Healthcare Business Sector

Healthcare CEOs drive strategic initiatives that enhance patient care quality and operational efficiency, directly impacting company performance metrics such as revenue growth, market share, and patient satisfaction scores. Their leadership in regulatory compliance, innovation, and stakeholder engagement plays a critical role in sustaining competitive advantage and financial stability within the healthcare sector.

Pfizer Inc.

Albert Bourla's estimated net worth of around $50 million stems from his executive compensation packages at Pfizer Inc., including salary, stock awards, bonuses, and accumulated Pfizer shares.

Merck & Co., Inc.

Robert M. Davis, CEO of Merck & Co., Inc., has an estimated net worth of around $50 million primarily due to his high executive salary, stock awards, performance bonuses, and accumulated equity holdings in Merck.

Sanofi S.A.

Paul Hudson's estimated net worth of around $40 million is primarily derived from his compensation as CEO of Sanofi S.A., including salary, bonuses, stock options, and past executive roles at Novartis and AstraZeneca.

GlaxoSmithKline plc (GSK)

Emma Walmsley, CEO of GlaxoSmithKline plc (GSK), has an estimated net worth of around $40 million due to her multi-million dollar annual salary, performance-based bonuses, and substantial shareholdings in GSK.

Novartis International AG

Vas Narasimhan, current CEO of Novartis International AG, has an estimated net worth of around $40 million due to his high executive compensation packages, stock awards, and long tenure at Novartis.

AstraZeneca plc

Pascal Soriot's estimated net worth of $40 million primarily stems from his long tenure as CEO of AstraZeneca plc, earning substantial annual compensation packages, stock awards, and performance bonuses.

Roche Holding AG

Thomas Schinecker's estimated net worth of around $30 million is primarily attributed to his executive compensation, stock grants, and performance-based bonuses at Roche Holding AG, as well as his long-standing career within the pharmaceutical industry.

Abbott Laboratories

Robert B. Ford's estimated net worth of around $85 million primarily derives from his compensation as CEO and President of Abbott Laboratories, as well as his significant holdings of company stock and equity-based awards.

Bristol Myers Squibb Company

Giovanni Caforio's estimated net worth of around $80 million is primarily attributed to his executive compensation, stock awards, and long-term incentives from his leadership roles at Bristol Myers Squibb Company.

Eli Lilly and Company

David A. Ricks, current CEO of Eli Lilly and Company, has an estimated net worth of around $100 million due to his high executive compensation, substantial stock awards, and long-term equity growth from his tenure at the global pharmaceutical leader.

Amgen Inc.

Robert A. Bradway, CEO of Amgen Inc., has amassed an estimated net worth of around $140 million primarily through his long-term executive compensation, bonuses, stock awards, and stock options at Amgen.

Gilead Sciences, Inc.

Daniel O'Day's estimated net worth of around $120 million is primarily due to his compensation as CEO of Gilead Sciences, Inc., including annual salary, stock options, and performance-based bonuses since joining in 2019.

Takeda Pharmaceutical Company Limited

Christophe Weber's estimated net worth of approximately $30 million USD reflects accumulated executive compensation, stock awards, and performance bonuses received during his tenure as CEO of Takeda Pharmaceutical Company Limited.

Cardinal Health, Inc.

Jason Hollar's estimated net worth of around $30 million primarily reflects his executive compensation at Cardinal Health, Inc., including salary, cash bonuses, and substantial stock awards.

Medtronic plc

Geoff Martha's estimated net worth of around $25 million is based on his executive compensation, stock ownership, and performance-based incentives at Medtronic plc and previous corporate roles.

Becton, Dickinson and Company (BD)

Tom Polen's estimated net worth of around $70 million stems from his significant stock ownership, executive compensation, and performance-based incentives as CEO of Becton, Dickinson and Company (BD).

Siemens Healthineers AG

Bernd Montag, current CEO of Siemens Healthineers AG, has an estimated net worth of around $15 million USD due to his executive compensation, long-term equity awards, and accumulated benefits from leading a major global medical technology company.

GE HealthCare Technologies Inc.

Peter J. Arduini's estimated net worth of around $50 million derives primarily from his compensation and stock holdings as CEO of GE HealthCare Technologies Inc., along with accumulated earnings from previous executive roles at Integra LifeSciences and Covidien.

Philips Healthcare (Koninklijke Philips N.V.)

Roy Jakobs, current CEO of Philips Healthcare (Koninklijke Philips N.V.), has a net worth estimated at around $5 million, primarily attributed to his executive compensation, stock awards, and long-term incentives from his leadership and previous management roles within the company.

Stryker Corporation

Kevin Lobo's estimated net worth of around $150 million is primarily derived from his long tenure as Stryker Corporation's CEO, significant stock ownership, equity awards, and annual compensation exceeding $10 million.

Boston Scientific Corporation

Michael F. Mahoney, CEO of Boston Scientific Corporation, has accrued an estimated net worth of around $150 million through substantial annual compensation, performance-based stock awards, and long-term equity growth linked to Boston Scientific's stock performance.

Cigna Group

David Cordani's estimated net worth of around $150 million stems from his long tenure as CEO and President of Cigna Group, where he has received substantial compensation packages including salary, bonuses, stock awards, and equity appreciation.

UnitedHealth Group Incorporated

Andrew Witty's estimated net worth of around $80 million is primarily attributed to his substantial compensation package as CEO of UnitedHealth Group Incorporated, including salary, bonuses, stock awards, and long-term equity incentives.

Anthem, Inc. (now Elevance Health)

Gail Boudreaux's estimated net worth of around $100 million is primarily derived from her compensation, stock holdings, and performance-based bonuses as CEO and President of Anthem, Inc.

Humana Inc.

Bruce D. Broussard's estimated net worth of around $100 million is primarily derived from his long tenure as CEO of Humana Inc. and significant stock ownership, equity awards, and executive compensation packages tied to the company's performance.

McKesson Corporation

Brian S. Tyler, CEO of McKesson Corporation, has an estimated net worth of around $70 million largely due to his executive compensation, substantial stock ownership, and long-term incentive awards accumulated during his tenure.

Walgreens Boots Alliance, Inc.

Tim Wentworth's estimated net worth of around $70 million stems from his extensive executive roles, notably as former CEO of Express Scripts and Cigna's Health Services division, accruing substantial compensation, stock awards, and incentives; his current CEO position at Walgreens Boots Alliance, Inc.

Quest Diagnostics Incorporated

James E. Davis's estimated net worth of around $35 million stems from his compensation as CEO of Quest Diagnostics, which includes salary, bonuses, stock awards, and options, as well as his significant holdings of Quest Diagnostics shares.

DaVita Inc.

Javier J. Rodriguez, CEO of DaVita Inc., has an estimated net worth of around $80 million, primarily derived from long-term executive compensation, equity awards, and stock ownership in the publicly traded DaVita Inc.

Fresenius Medical Care AG & Co. KGaA

Helen Giza's estimated net worth of around $15 million derives mainly from her executive compensation, stock awards, and incentives accumulated through her roles at Fresenius Medical Care AG & Co.

HCA Healthcare, Inc.

Samuel N. Hazen's estimated net worth of around $120 million is largely attributed to his long-term executive roles at HCA Healthcare, Inc., where his compensation includes a high base salary, substantial bonuses, stock awards, and accumulated stock options.

Tenet Healthcare Corporation

Saum Sutaria, CEO of Tenet Healthcare Corporation, has accrued a net worth of approximately $50 million through executive compensation packages, performance-based bonuses, stock awards, and long-standing roles within the healthcare sector.

Cleveland Clinic

Tomislav Mihaljevic's estimated net worth of around $20 million primarily stems from his executive compensation at Cleveland Clinic, which includes salary, bonuses, incentives, and benefits.

Mayo Clinic

Dr. Gianrico Farrugia's estimated net worth of around $15 million stems from his compensation as CEO of Mayo Clinic, which includes a high executive salary, performance bonuses, and significant retirement benefits.

Kaiser Permanente

Greg A. Adams, current CEO of Kaiser Permanente, has an estimated net worth of around $35 million, primarily due to his executive compensation packages, annual salary, performance bonuses, and stock or retirement benefits accrued over decades in senior healthcare leadership roles.

Mount Sinai Health System

Brendan Carr, the current CEO of Mount Sinai Health System, has an estimated net worth of around $5 million due to his executive compensation package, including salary, performance bonuses, and long-term incentives from managing a major nonprofit healthcare organization.

Allscripts Healthcare Solutions, Inc. (now Veradigm Inc.)

Rick Poulton's estimated net worth of around $50 million primarily derives from his executive compensation, substantial shareholdings in Allscripts Healthcare Solutions (now Veradigm Inc.), and years of stock awards and bonuses received as CEO and President.

Cerner Corporation (now Oracle Health)

Travis Dalton's estimated net worth of around $20 million USD stems from his executive compensation, stock awards, and performance incentives accrued through various leadership roles at Cerner Corporation and Oracle Health.

LabCorp (Laboratory Corporation of America Holdings)

Adam Schechter's estimated net worth of around $75 million is largely attributed to his executive compensation packages, stock holdings, and long-term equity awards received as CEO and former President of LabCorp.

Thermo Fisher Scientific Inc.

Marc N. Casper's estimated net worth of around $250 million primarily stems from his long tenure as CEO of Thermo Fisher Scientific Inc., significant equity compensation--including stock awards and options--and performance-based bonuses.

Illumina, Inc.

Jacob Thaysen's estimated net worth of around $15 million primarily results from executive compensation, stock grants, and bonuses received through leadership roles at Agilent Technologies and Illumina, Inc.

Regeneron Pharmaceuticals, Inc.

Leonard S. Schleifer's net worth, estimated at around $1.3 billion, primarily derives from his significant equity stake and long-term leadership at Regeneron Pharmaceuticals, Inc., a leading biotech firm.

Biogen Inc.

Christopher A. Viehbacher's estimated net worth of approximately $45 million largely stems from decades-long executive roles in biopharmaceutical firms, substantial stock holdings, options, and compensation packages received from Biogen Inc.

Zimmer Biomet Holdings, Inc.

Ivan Tornos, current CEO of Zimmer Biomet Holdings, Inc., has an estimated net worth of around $25 million due to accumulated executive compensation, stock awards, and vested options during his tenure with the company and prior industry roles.

Edwards Lifesciences Corporation

Bernard J. Zovighian's estimated net worth of around $25 million primarily stems from his compensation as CEO of Edwards Lifesciences Corporation, including salary, bonuses, stock awards, and previously accumulated equity from executive roles.

Bausch Health Companies Inc.

Thomas J. Appio's estimated net worth of around $25 million is primarily attributed to his executive compensation, equity awards, and stock ownership accumulated through his roles at Bausch Health Companies Inc.

ResMed Inc.

Michael J. Farrell, CEO of ResMed Inc., has an estimated net worth of about $70 million, primarily due to significant stock ownership, equity awards, and annual executive compensation.

Alcon Inc.

David J. Endicott's estimated net worth of around $40 million is primarily derived from his roles as CEO and executive at Alcon Inc., as well as accumulated stock awards, salary, performance bonuses, and previous executive positions in major pharmaceutical companies.

Dexcom, Inc.

Kevin Sayer's estimated net worth of around $70 million is primarily attributed to his executive compensation, significant stock ownership, and long tenure as CEO and Chairman of Dexcom, Inc., a leader in continuous glucose monitoring technology.

Insulet Corporation

James Hollingshead's estimated net worth of around $30 million primarily stems from his executive compensation, stock grants, and options at Insulet Corporation, as well as prior leadership roles at companies like Medtronic.

Vertex Pharmaceuticals Incorporated

Reshma Kewalramani's estimated net worth of $60 million is primarily attributed to her executive compensation, substantial stock holdings, and performance-based incentives as CEO of Vertex Pharmaceuticals Incorporated.

CSL Limited (CSL Behring)

Paul McKenzie's estimated net worth of around $25 million USD comes primarily from his executive compensation, stock options, bonuses, and long-term equity incentives received as CEO of CSL Limited (CSL Behring), a global biotechnology company with significant annual revenues.

Biomerieux SA

Pierre Boulud's estimated net worth of around $5 million is primarily attributed to his executive compensation, equity holdings, and performance-based incentives as CEO of bioMerieux SA.

Chugai Pharmaceutical Co., Ltd. (subsidiary of Roche)

Osamu Okuda's estimated net worth of around $5 million stems mainly from his executive compensation, stock ownership, and long tenure at Chugai Pharmaceutical Co., Ltd., a leading Japanese pharmaceutical company under Roche Group.

PerkinElmer, Inc. (now Revvity, Inc.)

Prahlad Singh's estimated net worth of around $30 million stems from his executive compensation, stock holdings, and performance-based bonuses as CEO of PerkinElmer, Inc.

Smith & Nephew plc

Deepak Nath, current CEO of Smith & Nephew plc, has an estimated net worth of around $20 million primarily from executive compensation, stock awards, and prior leadership roles at Siemens Healthineers and Abbott Laboratories.

Patterson Companies, Inc.

Don Zurbay's estimated net worth of around $15 million is primarily derived from his executive compensation, stock ownership, and long tenure at Patterson Companies, Inc.

Drägerwerk AG & Co. KGaA

Stefan Drager's estimated net worth of around $1.5 billion stems from his significant ownership stake and leadership role in Dragerwerk AG & Co. KGaA, a global leader in medical and safety technology.

Baxter International Inc.

Jose (Joe) E. Almeida's estimated net worth of around $70 million stems from over eight years as CEO and Chairman of Baxter International Inc., stock ownership, vested equity awards, and annual compensation exceeding $13 million.

Grifols, S.A.

Thomas Glanzmann, CEO of Grifols, S.A., has an estimated net worth of around $25 million, primarily attributed to his executive compensation and significant shareholdings in the biopharmaceutical company.

Bio-Rad Laboratories, Inc.

Norman Schwartz's estimated net worth of around $100 million derives mainly from his long tenure as CEO and Chairman of Bio-Rad Laboratories, Inc., substantial stock ownership, and compensation packages, including salary, bonuses, and equity awards.

Agilent Technologies, Inc.

Padraig McDonnell, current CEO of Agilent Technologies, Inc., has an estimated net worth of around $15 million primarily due to his executive salary, performance bonuses, and substantial company stock holdings accumulated through his leadership roles.

Siemens AG (Healthcare division)

Bernd Montag's estimated net worth of around $25 million is derived from his executive compensation at Siemens Healthineers, including salary, bonuses, stock awards, and long-term incentives.

Jerusalem Pharmaceuticals

Waleed Nasser, current CEO of Jerusalem Pharmaceuticals, is estimated to have a net worth of around $2 million primarily due to his executive compensation, company equity holdings, and related business assets within the regional pharmaceutical sector.

Aspen Pharmacare Holdings Limited

Stephen Saad's estimated net worth of around $1.2 billion primarily stems from his significant shareholding and leadership role in Aspen Pharmacare Holdings Limited, Africa's largest pharmaceutical company.

Mylan N.V. (now part of Viatris Inc.)

Scott A. Smith's estimated net worth of around $25 million stems from his executive compensation, stock awards, and bonuses accumulated during his leadership roles at various pharmaceutical companies, including his recent appointment as CEO of Viatris Inc.

Teva Pharmaceutical Industries Limited

Richard Francis, CEO of Teva Pharmaceutical Industries Limited, has an estimated net worth of around $12 million, largely accrued from executive salaries, performance bonuses, and stock awards from previous roles at Sandoz and his compensation package at Teva.

Sun Pharmaceutical Industries Ltd.

Dilip Shanghvi, founder and current CEO of Sun Pharmaceutical Industries Ltd., has amassed an estimated net worth of around $23 billion due to his significant equity stake and successful expansion of Sun Pharma into one of the world's largest generic drug manufacturers.

Astellas Pharma Inc.

Naoki Okamura's estimated net worth of approximately $10 million USD primarily reflects his cumulative compensation, bonuses, and stock holdings garnered through executive roles at Astellas Pharma Inc.

UCB S.A.

Jean-Christophe Tellier, CEO of UCB S.A., has amassed an estimated net worth of around $50 million primarily through his executive compensation, stock options, and long-term incentive plans accumulated over years at the biopharmaceutical firm.

Mallinckrodt Pharmaceuticals

Siggi Olafsson, CEO of Mallinckrodt Pharmaceuticals, has an estimated net worth of $20 million due to his executive compensation, stock awards, and leadership roles at major pharmaceutical companies like Actavis and Hikma.

Hikma Pharmaceuticals PLC

Riad Mishlawi's estimated net worth of around $10 million primarily derives from his executive compensation and long-term incentive plans at Hikma Pharmaceuticals PLC, including salary, bonuses, and vested company shares.

Allergan plc (now part of AbbVie Inc.)

Richard A. Gonzalez's estimated net worth of around $90 million is primarily attributed to his long tenure as Chairman and CEO of AbbVie Inc., which acquired Allergan plc, and is based on his accumulated stock awards, salary, bonuses, and other executive compensation reported in SEC filings.

AbbVie Inc.

Richard A. Gonzalez, CEO of AbbVie Inc., has an estimated net worth of around $80 million, largely accumulated through his executive compensation, performance-based stock awards, and long-term investments in AbbVie shares.

Otsuka Pharmaceutical Co., Ltd.

Makoto Inoue's estimated net worth of around $10 million USD is based on his executive compensation, stock holdings, and performance incentives as CEO of Otsuka Pharmaceutical Co., Ltd.

Exelixis, Inc.

Michael M. Morrissey's estimated net worth of around $60 million primarily results from his long-term tenure as CEO of Exelixis, Inc., significant stock ownership, equity awards, and substantial executive compensation packages.

Jazz Pharmaceuticals plc

Bruce Cozadd's estimated net worth of around $150 million primarily stems from his long-term equity holdings, executive compensation, and stock options as CEO and co-founder of Jazz Pharmaceuticals plc.

Horizon Therapeutics plc

Timothy P. Walbert's estimated net worth of around $150 million is primarily attributed to his executive compensation, equity holdings, and stock sales from his long tenure as CEO and Chairman of Horizon Therapeutics plc.

BioNTech SE

Ugur Sahin's net worth is estimated at around $2 billion primarily due to his significant equity stake in BioNTech SE, whose valuation soared following the commercial success of its COVID-19 vaccine developed with Pfizer.

Moderna, Inc.

Stephane Bancel's estimated net worth of around $4 billion is primarily driven by his substantial equity stake in Moderna, Inc. and the company's dramatic valuation increase due to its pioneering development and global sales of COVID-19 vaccines.

Emergent BioSolutions Inc.

Robert G. Kramer, CEO of Emergent BioSolutions Inc., has an estimated net worth of around $50 million primarily from his long-term executive compensation, stock awards, and performance-based bonuses linked to company milestones and share price growth.

Catalent, Inc.

Alessandro Maselli's estimated net worth of around $10 million is primarily derived from his salary, bonuses, and equity compensation earned as CEO and other executive roles at Catalent, Inc.

West Pharmaceutical Services, Inc.

Eric M. Green's estimated net worth of around $40 million is primarily attributed to his substantial holdings of West Pharmaceutical Services, Inc. stock and compensation packages, including salary, bonuses, and equity awards earned during his tenure as CEO.

Dentsply Sirona Inc.

Simon D. Campion's estimated net worth of around $15 million derives from his executive compensation, stock awards, and bonuses received as CEO and from prior leadership roles at Dentsply Sirona Inc.

St. Jude Medical, Inc. (now part of Abbott Laboratories)

Robert B. Ford, current CEO of Abbott Laboratories (which acquired St. Jude Medical, Inc.), has an estimated net worth of around $55 million largely due to compensation packages, stock grants, and long-term incentives accumulated since joining Abbott in 1996 and becoming CEO in 2020.

Hospira, Inc. (now part of Pfizer Inc.)

Scott Gottlieb's estimated net worth of around $20 million stems from his executive compensation at Hospira, subsequent roles as FDA Commissioner, and board positions at major pharmaceutical companies like Pfizer and Illumina.

Covidien Ltd. (now part of Medtronic plc)

Geoffrey S. Martha, now CEO of Medtronic plc (which acquired Covidien Ltd.), has an estimated net worth of around $60 million, primarily from equity awards, executive compensation, and stock holdings accrued through his leadership roles at Medtronic and previously at Covidien.